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The female nuclear medicine patient is of special concern in evaluating radiation dose and risk in
nuclear medicine. The female's overall body size and organ sizes generally are smaller than
those of her male counterpart (thus her radiation doses will be higher, given the same amounts
of administered activity and similar biokinetics); female gonads are inside the body instead of
outside and are near several organs often important as source organs in internal dosimetry
(urinary bladder, liver, kidneys, intestines); risk of breast cancer is significantly higher among
females than males; and in the case of pregnancy, exposure to radiation of the embryo/fetus
and the nursing infant are of special concern in such an analysis. All these concerns are
addressed in this study through a comparative study of radiation doses for males and females
over a large number (-60) of nuclear medicine studies and through a study of what is known
about radiation dosimetry in pregnancy and breast feeding. It was found that women's critical
organ doses and effective doses (as defined by the International Commission on Radiological
Protection 60 [ICRP'601) are about 25% higher than those for men across all these studies.
Women's gonad doses, however, may be as much as 10 to 30 times higher than those in men,
although 2- to 3-fold differences are common. Many radiopharmaceuticals are administered to
women of childbearing age; however, little is known about how much activity crosses the
placenta and about the biokinetics in the fetus should it occur. Nonetheless, dose estimates are
provided at four stages of pregnancy (early, 3-month, 6-month, and 9-month gestation) for a
large number of radiopharmaceuticals, whether or not quantitative estimates of placental
crossover can be made. Many radiopharmaceuticals are also excreted in breast milk of nursing
mothers. Breast feeding interruption schedules are suggested through analysis of the observed
kinetics of these pharmaceuticals and an assumed dose limit of 1 mSv (effective dose
equivalent) to the infant. -Environ Health Perspect 105(Suppl 6):1403-1409 (1997)
Key words: radiation, radiation dosimetry, internal dosimetry, nuclear medicine, women's
health issues
Introduction
The risk-benefit analysis for patients in exposure. However, the female nuclear
nuclear medicine necessarily uses calculated medicine patient is ofspecial concern to
estimates ofradiation doses (absorbed dose, the evaluation ofradiation dose and risk in
dose equivalent, effective dose, etc.) for nuclear medicine. The female's overall
exposed persons. Analysis is different than body size and organ sizes are generally
that used in other situations, as the person smaller than those ofher male counterpart
receiving the radiation dose usually is also (thus her radiation doses will be higher,
the one who directly benefits from the given the same amounts of administered
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activity and similar biokinetics); female
gonads are inside the body instead ofout-
side and are near several organs often
important as source organs in internal
dosimetry (urinary bladder, liver, kidneys,
intestines); risk ofbreast cancer is signifi-
cantly higher among females than males;
and in the case ofpregnancy, exposure of
the embryo/fetus and the nursing infant is
ofspecial concern in such an analysis. This
study analyzes the differences in organ
doses and effective doses [as defined in
International Commission on Radiological
Protection 60 (ICRP 60) (1)], and gonad
doses between male and female nuclear
medicine patients. Radiation dose estimates
for many nuclear medicine procedures
involving a wide variety of radionuclides
and pharmaceuticals (even some that are no
longer in common use, in order to broaden
the spectrum of observed results) were
developed for standard adult males (70 kg)
and females (57 kg), and differences in
organ, gonad, and effective doses were stud-
ied. Results from several previous studies on
radiation dosimetry in pregnancy and lacta-
tion were included to provide a more com-
plete discussion ofwomen's health concerns
in nuclear medicine.
This study provides only estimates of
radiation dose for the adult female from
nuclear medicine procedures. This infor-
mation may be used to analyze risks that
women might incur from these procedures
and to determine how these risks may dif-
fer from those incurred by men; such an
analysis is outside the scope ofthis work.
Additional information needed to com-
plete such an analysis would include the
amount ofactivity administered per study,
the number ofstudies performed per year,
and estimates ofthe risk incurred per unit
ofdose received. This information changes
frequently and should be obtained at the
time any risk-benefit analysis is performed;
thus, no attempt was made to include such
an analysis in this work.
Methods
A wide variety of nuclear medicine studies
(-60) were chosen for the comparative
study of organ, gonad, and effective doses
between men and women. Standard bio-
kinetic models were taken from ICRP
Publication 53 (2) or, in some cases, from
internal files at the Radiation Internal Dose
Information Center (RIDIC) in Oak
Ridge, Tennessee. (This center maintains
up-to-date information on the kinetics and
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Table 1. Critical organ, gonad, and effective doses for females and males for the radiopharmaceuticals studied.
Critical organ doses, mGy/MBq Gonad doses, mGy/MBq Effective doses, mSv/MBq
Radiopharmaceutical Females Males Organ Females Males Females Males
Au-198Bcolloid 12.9 10.6 Spleen 0.12 0.042 i.16E+00 9.14E-0Oi
C-il1 Tryptophane 0.0267 0.0245 Kidneys 0.004 0.0028 5.03E-03 4.32E-03
C-il1 lomazenil 0.127 0.099 UBC 0.00437 0.0022 1.39E-02 1.06E-02
Co-57 Vitamin B-12, nor/fIsh 30 23 Liver 1.1 0.46 2.90E+00 2.25E+00
Co-57 Vitamin B-12, PA/fIsh 3.8 3 Liver 0.3 0.068 5.99E-01 4.90E-01
Co-58 Vitamin B-i2, nor/fish 44 35 Liver 2.65 1 5.45E+00 4.35E+OO
Co-58 Vitamin B-i12, PA/fish 5.8 4.7 Liver 1.53 0.22 1 .59E+00 1 .30E+00
Co-6O Vitamin B-12, nor/fish 680 550 Liver 37 16 8.01 E+Oi1 6.39E+01
Co-60 Vitamin 6-12, PA/fish 88 71 Liver 7.44 2.2 1.24E+01 1.OOE+01
F-18 FOG 0.26 0.19 UBC 0.019 0.013 3.1iOE-02 2.41E-02
F-lB NaF 0.35 0.25 UBC 0.014 0.0078 3.1iOE-02 2.31 E-02
Ga-67 Citrate 0.33 0.32 BS 0 1 0.055 1 .20E-01 1.OGE-01
Hg-197 Chlormerodrin 2.4 2.2 Kidneys 0.0105 0.006 1.13E-01 9.66E-02
1-123 Hippuran 0.44 0.3 UBC 0,013 0.007 2.90E-02 2.01 E-02
1-123 IMP 0.082 0.057 UBC 0.017 0.01 2.34E-02 1.82E-02
1-123 mlBG 0.14 0.094 UBC 0.012 0.0069 2.21 E-02 1.66E-02
1-123 Nal 4.1 3.4 Thyroid 0.015 0.0051 2.43E-0O1 2.OOE-01
I-125HSA 1.58 1.22 Heartwall 0.249 0.167 2.91E-0O1 2.29E-01
1-125 mlBG 0.3 0.22 Liver 0.02 0.013 4.86E-02 3.63E-02
1-125 Nal 250 210 Thyroid 0.0145 0.0065 1.35E+01 1.13E+01
1-131 Hippuran 2.0 1.4 UBC 0.031 0.017 1.17E-01 8.58E-02
1-131 HSA 3.5 3 Heart wall 0.52 0.35 9.35E-0O1 7.43E-01
1-131 MAA 2.9 2.3 Lungs 0.0565 0.027 6.06E-01 4.72E-01
1-131 mIBG 1 0.78 Liver 0.093 0.058 1.95E-01 1.49E-01
1-131 Nal 420 340 Thyroid 0.06 0.028 2.24E+01 1.84E+01
1-131 Rose bengal 9 8.4 LLI 0.5 0.037 1.33E+00 1.21E+00
In-il OTPA 0.64 0.43 UBC 0.032 0.019 5.02E-02 3.56E-02
In-ill Platelets 6.2 5.2 Spleen 0.17 0.09 3.95E-01 3.26E-0Oi
In-ill RBCs 0.91 0.76 Spleen 0.23 0.14 2.24E-01 1.85E-01
In-ill WBCs 7.0 5.9 Spleen 0.16 0.03 4.88E-01 4.09E-01
In-il 1 Pentetreotide 0.73 0.67 Kidneys 0.06 0.026 1.03E-01 8.14E-02
Kr-81 m 0.00025 0.0002 Lungs 1.70E-07 1 .OOE-08 3.39E-05 2.65E-05
N-13 NH3 0.0091 0.0069 UBC 0.0022 0.0014 2.56E-03 2.01 E-03
P-32 Na2PO4 10 10 BS 0.98 0.76 2.29E+00 1.80E+00
Tc-99m Albmn mcrsph 0.074 0.058 Lungs 0.003 0.0015 1 .77E-02 1 .45E-02
Tc-99m DISIDA 0.12 0.11 GB 0.024 0.0017 2.15E-02 1.78E-02
Tc-99m DMSA 0.21 0.19 Kidneys 0.0045 0.0018 1.07E-02 9.12E-03
Tc-99m DTPA - iv 0.11 0.077 UBC 0.0068 0.0038 9.66E-03 7.09E-03
Tc-99m DTPA - aersl 0.046 0.032 UBC 0.0041 0.0017 7.50E-03 5.76E-03
Tc-99m Glucoheptonate 0.11 0.074 UBC 0.0069 0.0037 1 .OOE-02 7.42E-03
Tc-99m HOP 0.051 0.052 BS 0.0052 0.0023 6.07E-03 4.80E-03
Tc-99m HEDP 0.058 0.041 UBC 0.0047 0.0026 6.55E-03 4.96E-03
Tc-99m HMPAO 0.058 0.051 GB 0.0051 0.0023 1 .29E-02 1 .09E-02
Tc-99m HSA 0.025 0.021 Heart waIl 0.0051 0.0029 7.54E-03 6.21 E-03
Tc-99m MAA 0.085 0.067 Lungs 0.0022 0.0011 1 .54E-02 1 .20E-02
Tc-99m MAG3 0.2 0.14 UBC 0.0085 0.0046 1.40E-02 9.99E-03
Tc-99m MOP 0.035 0.035 BS 0.0041 0.0023 6.19E-03 4.75E-03
Tc-99m MIBI/stress 0.047 0.04 ULI 0.014 0.0031 1.31 E-02 1.07E-02
Tc-99m MIBI/rest 0.058 0.05 ULI 0.018 0.0035 1.63E-02 1.33E-02
Tc-99m Pertechnetate 0.034 0.036 UBC 0.01 0.0033 1.40E-02 1.14E-02
Tc-99m PYP 0.039 0.038 BS 0.0047 0.0026 6.31 E-03 4.95E-03
Tc-99m RBCs/in vitro 0.03 0.021 UBC 0.0057 0.0033 7.83E-03 6.11 E-03
Tc-99m RBCs/in vivo 0.019 0.016 Heart waIl 0.0058 0.0033 7.59E-03 5.99E-03
Tc-99m RBCs/heat 0.78 0.65 Spleen 0.00208 0.00047 2.66E-02 2.24E-02
Tc-99m Slfr cld/nor 0.11 0.086 Liver 0.0022 0.00022 1 .03E-02 8.04E-03
Tc-99m Slfr cld/dis 0.26 0.22 Spleen 0.004 0.00083 1 .59E-02 0.32E-02
Tc-99m Slfr cld/oral 0.13 0.12 ULI 0.03 0.00125 2.88E-02 2.68E-02
Tc-99m Teboroxime 0.042 0.036 ULI 0.012 0.0019 1 .23E-02 1 .OOE-02
Tc-99m WBCs 0.22 0.18 Spleen 0.0048 0.00084 1.54E-02 1.29E-02
T1-201 Chloride 0.66 0.62 Thyroid 0.12 0.2 1.65E-01 2.74E-01
Xe-i127, 5-min rebreath 0.00063 0.00049 Lungs 0.00026 0.00016 2.92E-04 2.36E-04
Xe-i133, 5-min rebreath 0.0014 0.0011 Lungs 0.00025 0.00018 3.86E-04 3.04E-04
Abbreviations: BS, bone surfaces; UBC, urinary bladder contents;- ULI, upper large intestine; LLI, lower large intestine; GB, gall bladder;, nor, normal subjects; aersl, aerosol;
fish, flushing dose administered; PA, percutaneous anemia subjects; FOG, flurodeoxyglucose; NaF', sodium fluoride; IMP, iodoamphetamine; mIBG, metaiodobenzylguanidine;
Nal, sodium iodide; HSA, human serum albumin; MAA, macroaggregated albumin; DTPA, diethylentriaminpentaacetic acid; RBC, red blood cells; WBC, white blood cells; NH3,
ammonia; Na2PO4, sodium phosphate; DISIDA, disofenin (iminodiacetic acid derivative); DMSA, dimercaptosuccinic acid; HDP, hydroxymethylene diphosphonate; HEDP,
hydroxyethylidene diphosphonate; HMPAO, hexamethylpropyleneamineoxine; MAG3, mercaptoacetylglycylglycylglycine; MOP, methylene diphosphonate; MIBI, methoxy-
isobutyl isonitrile; PYP, pyrophosphate; slfr cld, sulfur colloid; dis, diseased subjects; rebreath, rebreathing.
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dosimetry of radiopharmaceuticals. In
addition to keeping abreast ofmaterial in
the open literature, RIDIC often has access
to information on biokinetics or dosimetry
ofthese agents through its support role of
the nuclear medicine community.) Esti-
mates of the residence times (3) for all sig-
nificant source organs were established
using standard biokinetic models and
employing standard adult male (70 kg) and
standard adult female (57 kg) phantoms
(5,6) as employed in and entered into the
MIRDOSE 3.1 software (4). Radiation
doses per unit administered activity to the
critical organ (single organ receiving the
highest radiation dose), the gonads, and the
breast were noted and compared. In these
phantoms, the breast tissue represents the
female breast tissue; no comparisons were
made with the dose to male breast tissue, as
the latter is not easily evaluated. Therefore,
only the female breast dose was calculated
and tabulated simply for information.
Effective doses for males and females were
also reported and compared.
Results from two recent studies
performed by RIDIC were also included in
this study-one on radiation dosimetry for
the embryo/fetus for the pregnant nuclear
medicine patient and one on the dose to
the nursing infant for breast-feeding
mothers who received radiopharmaceuti-
cals. Extensive detail on the methods used
in these two studies are published else-
where (7,8), so only a brief summary is
provided here. For the embryo/fetal dose
study, an informal survey of a number of
nuclear medicine institutions first was per-
formed to determine what radiopharma-
ceuticals are commonly administered to
women ofchildbearing age as well as what
procedures are used to prevent the inadver-
tent administration of radiopharmaceuti-
cals to pregnant women. The literature was
then studied to find as many sources of
information as possible about the placental
crossover of radiopharmaceuticals. Much
of the available information came from
animal studies. Where possible, models of
the placental crossover ofdifferent radio-
pharmaceuticals as functions of gestation
were developed. Next, residence times for
activity in the maternal organs (as used in
the comparative studies oforgan and gonad
doses ) were combined with estimated resi-
dence times for the placenta and fetus and
used with the four phantoms (adult female
in early pregnancy, and at 3-month,
6-month, and 9-month gestation) in the
MIRDOSE 3.1 software, (4,6). There are
many radiopharmaceuticals that can be
administered to women ofchildbearing age
for which no informationabout placental
crossover could be found in the literature.
In these cases, radiation dose estimates to
the fetus were developed using only an
estimate of the residence times in the
mother's organs. It was not thought pru-
dent to just assume values for placental
crossover (e.g., 0.5, 1, 5%) with no litera-
ture support. These radiation doses, there-
fore, may underestimate fetal doses in cases
in which significant placental crossover
occurs, but at present they represent the
best estimates available. The dose to the
embryo/fetus is thus reported for many
radiopharmaceuticals at these four assumed
stages ofpregnancy. In the study on breast
feeding, values reported in the literature for
the excretion of many radiopharmaceuti-
cals in the breast milk of nursing mothers
participating in nuclear medicine studies
were used in a standard model for nursing
that assumed the infant consumed 1000
ml/day of milk, feeding at 3-hr intervals,
starting either immediately (3 hr) after the
administration ofthe pharmaceutical or at
fixed interruption times (6-hr, 12-hr,
24-hr, etc.). From this analysis, an estimate
was obtained ofthe activity ingested by the
infant; the activity ingested was assumed to
be quickly and instantaneously absorbed
into the bloodstream and thereafter to have
biokinetics in the infant similar to that in
the adult. Organ residence times were thus
assigned, and organ doses and effective dose
equivalents [as defined in ICRP Publication
30 (9)] were calculated. Effective dose
equivalent (9) instead ofthe effective dose
(1) was used because the study was com-
missioned by the U.S. Nuclear Regulatory
Commission (USNRC), which still uses
the effective dose equivalent as its regula-
tory basis. [The numerical difference
between effective dose equivalent and
effective dose in nuclear medicine doses is
usually very small (10).] The USNRC
assigned an acceptable dose level of 1 mSv
effective dose equivalent to the infant. If
the worst-case dose to the infant did not
exceed this amount, no interruption of
breast feeding was indicated; otherwise the
time interval was calculated for which
breast feeding had to be stopped to ensure
a dose below this level.
Results
Table 1 shows the actual critical organ
doses, gonad doses, and effective doses for
Table 2. Ratios ofcritical organ, gonad, and effective dosesforfemales/males forthe radiopharmaceuticals studied.
Ratios Ratios
Radiopharmaceutical Critical organ Gonad ED Radiopharmaceutical Critical organ Gonad ED
Au-198 Colloid 1.22 2.86 1.27 Kr-81m 1.25 17.00 1.28
C-li Tryptophane 1.09 1.43 1.16 N-13 NH3 1.32 1.57 1.27
C-11 lomazenil 1.28 1.99 1.31 P-32 Na2PO4 1.00 1.29 1.27
Co-57 B-12, nor/fish 1.30 2.39 1.29 Tc-99m Albmn mcrsph 1.28 2.00 1.22
Co-57 B-12, PA/flsh 1.27 4.41 1.22 Tc-99m DISIDA 1.09 14.12 1.21
Co-58 B-12, nor/flsh 1.26 2.65 1.25 Tc-99m DMSA 1.11 2.50 1.17
Co-58 B-12, PA/fish 1.23 6.95 1.22 Tc-99m DTPA-iv 1.43 1.79 1.36
Co-60 B-12, nor/flsh 1.24 2.31 1.25 Tc-99m DTPA-aersl 1.44 2.41 1.30
Co-60 B-12, PA/fish 1.24 3.38 1.24 Tc-99m Glucoheptonate 1.49 1.86 1.35
F-18 FDG 1.37 1.46 1.29 Tc-99m HDP 0.98 2.26 1.26
F-18 NaF 1.40 1.79 1.34 Tc-99m HEDP 1.41 1.81 1.32
Ga-67 Citrate 1.03 1.82 1.20 Tc-99m HMPAO 1.14 2.22 1.18
Hg-197 Chlormerodrin 1.09 1.75 1.17 Tc-99m HSA 1.19 1.76 1.21
1-123 Hippuran 1.47 1.86 1.44 Tc-99m MAA 1.27 2.00 1.28
1-123 IMP 1.44 1.70 1.29 Tc-99m MAG3 1.43 1.85 1.40
1-123 mlBG 1.49 1.74 1.33 Tc-99m MDP 1.00 1.78 1.30
1-123 Nal 1.21 2.94 1.22 Tc-99m MIBI-stress 1.18 4.52 1.22
1-125 HSA 1.30 1.49 1.27 Tc-99m MIBI-rest 1.16 5.14 1.23
1-125 mlBG 1.36 1.54 1.34 Tc-99m Pertechnetate 0.94 3.03 1.23
1-125 Nal 1.19 2.23 1.19 Tc-99m PYP 1.03 1.81 1.27
1-131 Hippuran 1.43 1.82 1.36 Tc-99m RBCs/in vitro 1.43 1.73 1.28
1-131 HSA 1.17 1.49 1.26 Tc-99m RBCs/in vivo 1.19 1.76 1.27
1-131 MAA 1.26 2.09 1.28 Tc-99m RBCs/heat 1.20 4.43 1.19
1-131 mlBG 1.28 1.60 1.31 Tc-99m Slfrcld/nor 1.28 10.00 1.28
1-131 Nal 1.24 2.14 1.22 Tc-99m Slfrcld/dis 1.18 4.82 1.20
1-131 Rose bengal 1.07 13.51 1.10 Tc-99m Slfrcld/oral 1.08 24.00 1.07
In-11 DTPA 1.49 1.68 1.41 Tc-99mTeboroxime 1.17 6.32 1.23
In-111 Platelets 1.19 1.89 1.21 Tc-99mWBCs 1.22 5.71 1.19
In-111 RBCs 1.20 1.64 1.21 TI-201 Chloride 1.06 0.60 0.60
In-111 WBCs 1.19 5.33 1.19 Xe-127, 5-min rebreath 1.29 1.63 1.24
In-111 Pentetreotide 1.09 2.31 1.27 Xe-133, 5-minrebreath 1.27 1.39 1.27
Means 1.23 3.54 1.25
Standard deviations 0.14 4.09 0.11
ED, effective dose.
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Table 3. Breast doses estimated forthe radiopharmaceuticals studied.
Radiopharmaceutical Breastdose, mGy/MBq Radiopharmaceutical Breast dose, mGy/MBq
Au-i198 colloid 0.124 Kr-81m 4.60e-06
Co-57 B-12, Nor/fish 0.986 N-13 NH3 0.001 63
Co-57 B-12, PA/fish 0.126 . P-32 Na2PO4 0.98
Co-58 B-12, Nor/fish 2.47 Tc-99m Albmn Mcrsph 0.00516
Co-58 B-12, PA/fish 0.327 Tc-99m DMSA 0.00173
Co-60 B-i2, Nor/fish 39.7 Tc-99m DTPA-iv 0.00137
Co-60 B-12, PA/fish 5.08 Tc-99m DTPA-aersl 0.00162
F-18 FDG 0.0117 Tc-99m Glucoheptonate 0.00141
F-18 NaF 0.00337 Tc-99m HOP 0.001D63
Ga-67 Citrate 0.0592 Tc-99m HEDP 0.001533
Hg-i197 Chlormerodrin 0.00501 Tc-99m HMPAO 0.0023
1-123 Hippuran 0.000236 Tc-99m HSA 0.00457
1-123 IMP 0.011 Tc-99m MMA 0.00551
1-123 mlBG 0.00515 Tc-99m MAG3 0.000142
1-123 Nal 0.0039 Tc-99m MOP 0.00121
1-125 HSA 0.207 Tc-99m MIBI/stress 0.00212
1-125 mIBG 0.0156 Tc-99m Pertechnetate 0.00207
1-125 Nal 0.00889 Tc-99m PYP 0.00192
1-131 Hippuran 0.000935 Tc-99m RBCs/in vitro 0.00382
1-131 HSA 0.509 Tc-99m RBCs/in vivo 0.00414
1-131 MAA 0.0988 Tc-99m RBCs/heat 0.00185
1-131 mlBG 0.0665 Tc-99m Slfrcld/nrml 0.00268
1-131 Nal 0.0556 Tc-99m Slfrcid/dis 0.00236
1-131 Rose bengal 0.00694 Tc-99m Slfrcld/oral 0.000491
In-11 DTPA 0.00447 Tc-99m Teboroxime 0.0026
In-ill Platelets 0.113 Tc-99m WBCs 0.00224
In-1il RBCs 0.137 TI-201 Chloride 0.0407
In-111 WBCs 0.0802 Xe-127, 5-min rebreath 0.000182
In-111Pentetreotide 0.0155 Xe-133, 5-minrebreath 0.00023
the radiopharmaceuticals studied in this
report. Table 2 shows the ratios of these
quantities for the reference adult female/ref-
erence adult male. Table 3 shows the breast
doses estimated for the adult female for the
radiopharmaceuticals studied in this report.
Figures 1 to 3 show plots ofthese results,
in histogram format. Figure 4 shows a plot
of the breast doses, also in histogram
format. The x axes in Figures 1 and 3 are
linear and in Figures 2 and 4 logarithmic.
Table 4 is a summary ofabsorbed doses
to the fetus from administration ofradio-
pharmaceuticals to pregnant women (7).
These doses are expressed as absorbed dose
to the embryo/fetus per unit activity
administered to the mother. Shaded rows
in the table indicate that some information
was available on placental crossover and
was used in the estimates. Table 5 is a sum-
mary ofthe recommendations for possible
interruption ofbreast feeding in the nurs-
ing mother given a radiopharmaceutical,
given the 1-mSv infant dose criterion.
Further details on the dosimetry are given
in the USNRC (8).
Discussion
As seen in Table 2 and in Figures 1 and 3,
the ratio ofthe standard female's critical
organ doses and effective doses over a wide
14 Mean1.23
Standard deviation0.14
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Figure 1. Frequency plot of the ratios (female/male) of
critical organ doses calculated inthis study.
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Figure 3. Frequency plot ofthe ratios (female/male) of
effective doses calculated in this study.
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Figure 2. Frequency plot ofthe ratios (female/male) of Figure 4. Frequency plot of the female breast doses
gonad doses calculated in this study. calculated in this study.
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Table 4. Absorbed dose estimates tothe embryo/fetus perunit activityof radiopharmaceutical administered to the mother(shading indicates maternal and fetal self-dose
contributions) a
Radiopharmaceutical
Co-57Vitamin B-1,nor/fish
Co-57Vitamin B-12,nor-nofish
Co-57VitaminB-12,PA-fish
Co-57VitaminB-12, PA-nofish
Co-5BVitaminB-12, nor-fish
Co-58Vitamin B-12, nor-nofish
Co-58Vitamin B-12, PA-fish
Co-58VitaminB-12, PA-nofish
Co-60Vitamin B-12, nor-fish
Co-60VitaminB-12, nor-nofish
Co-60Vitamin 8-12, PA-fish
Co-60Vitamin B-12, PA- nofish
F-18FDG
F-18Sodiumfluoride
Early, mGy/MBq
1.OE+0o
1.5E+00
2.1E-01
2.8E-01
2.5E+00
3.7E+00
8.3E-01
9.8E-01
3.7E+01
5.5E+01
5.9E+00
8.3E+00
2.7E-02
2.2E-02
Typeofpregnancy
3-Month, mGy/MBq 6-Month, mGy/MBq
6BE-01 8.4E-01
1.OE+00 1.2E+00
1.7E-01 .7E-01
2.1E-01 2.2E-01
1.9E+00 2.1E+00
2.8E+00 3.1E+00
7.4E-01 6.4E-01
8.5E-01 7.6E-01
2.8E+01 3.1E+01
4.2E+01 4.7E+01
4.7E+00 4.8E+00
6.5E+00 6.8E+00
1.7E-02 9.4E-03
1.7E-02 7.5E-03
9-Month,mGy/MBq
8.8E-01
1.3E+00
1.5E-1
2.OE-01
2.1E+00
3.1E+00
4.8E-01
6.OE-01
3.2E+01
4.7E+01
4.5E+00
6.5E+00
8.1E-03
6.8E-03
1-123Hippuran 3.1E-02 2.4E-02 8.4E-03 7.9E-03
1-123 IMP 1.9E-02 1.1E-02 7.1E-03 5.9E-03
1-123MIBG1 1.8E-02 1.2E-02 6.8E-03 6.2E-03
1-124Sodium iodide 1t4E-01 1.DE-01 5.9E-02 4.6E-02
1-125 HSA 2.5E-01 7.8E-02 3.8E-02 2.6E-02
1-125 IMP 3.2E-02 1.3E-02 4.8E-03 3.6E-03
1-125 MIBG 2.6E-02 i.iE-02 4.1E-03 3.4E-03
1-125Sodium iodide 1.8E-02 9.5E-03 3.5E-03 2.3E-03
1-126Sodium iodide 7.8E-02 5.1E-02 3.2E-02 2.6E-02
1-130Sodium iodide 1.8E-01 .3E-01 7.6E-02 5.7E-02
1-131 Hippuran 6.4E-02 5.OE-02 1.9E-02 1.8E-02
1-131 HSA 5.2E-01 1BE-01 1.6E-01 1.3E-01
1-131 MAA 6.7E-02 4.2E-02 4.OE-02 4.2E-02
1-131 MIBG 1.lE-01 5.4E-02 3.8E-02 3.5E-02
1-131 Rosebengal
In-1l1 DTPA
in-i11 Pentetreotide
In-111 Platelets
ln-i11 RBCs
In-111 WBCs
Tc-99mAlbmmcrsph
2.2E-01
6.5E-02
8.2E-02
1.7E-1
2.2E-01
1.3E-01
4.1E-03
2.2E-01
4.8E-02
6.OE-02
1.E-01
1.3E-01
9.6E-02
3.OE-03
.1 ee n A
1.6E-01
2.OE-02
3.5E-02
9.9E-02
1.1E-01
9.6E-02
2.5E-03
Tc-99mWBCs
TI-201 Chloride
Xe-127, 5-minrebreath,
5-literspirometervol
9OE-02
1.8E-02
3.1E-02
8.9E-02
8.6E-02
9.4E-02
2.1E-03
(Continuedon nextpage)
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Table 4. (Continued)
Type of pregnancy
Radiopharmaceutical Early, mGy/MBq 3-Month, mGy/MBq 6-Month, mGy/MBq 9-Month, mGy/MBq
Xe-127, 5-min rebreath, 2.3E-04 1.3E-04 1.0E-04 8.4E-05
7.5-liter spirometervolume
Xe-127, 5-min rebreath, 2.3E-04 1.4E-04 1.1E-04 9.2E-05
10 liter spirometer volume
Xe-133, 5-min rebreath, 4.1E-04 4.8E-05 3.5E-05 2.6E-05
5-liter spirometer volume
Xe-133, 5-min rebreath, 2.2E-04 2.6E-05 1.9E-05 1.5E-05
7.5 liter spirometer volume
Xe-133,-5 min rebreath, 2.5E-04 2.9E-05 2.1E-05 1.6E-05
10-liter spirometer volume
Xe-133, injection 4.9E-06 1.OE-06 1.4E-06 1.6E-06
"Data from Russell et al. (7).
Table 5. Summary of recommendations for radiopharmaceuticals excreted in the breast milk.
Administered activity,
Radiopharmaceutical MBq (mCi)
Ga-67 Citrate 185(5.0)
Tc-99m DTPA 740 (20)
Tc-99m MAA 148 (4)
Tc-99m Pertechnetate 1110(30)
1-131 Nal 5550 (150)
Cr-51 EDTA 1.85 (0.05)
Tc-99m DISIDA 300 (8)
Tc-99m Glucoheptonate 740 (20)
Tc-99m HAM 300 (8)
Tc-99m MIBI 1110 (30)
Tc-99m MDP 740 (20)
Tc-99m PYP 740(20)
Tc-99m RBCs/in vivo 740 (20)
Tc-99m RBCs/in vitro 740 (20)
Tc-99m sulfur colloid 444 (12)
In-111 WBCs 18.5 (0.5)
1-123 Nal 14.8 (0.4)
1-123 OIH 74(2)
1-123 mlBG 370 (10)
1-125 OIH 0.37 (0.01)
1-131 OIH 11.1 (0.3)
Tl-201 111 (3)
Tc-99m DTPA aerosol 37 (1)
Tc-99m WBCs 185 (5)
Tc-99m MAG3 370 (10)
Xe-133 gas
aData from the USNRC (8).
Counseling
needed?
Yes
No
Yes
Yes
Yes
No
No
No
No
No
No
No
Yes
No
Yes
Yes
No
No
Yes
No
No
Yes
No
Yes
No
No
range of studies is about 1.25, with a
relatively small standard deviation (less
than 10%). This is reasonable based on
the ratio ofbody weights (57 kg vs 70 kg),
which represents about a 20% difference.
Individual organ differences vary, but
these differences basically represent the
effect of the smaller mass. The gonad
doses, however, have a mean ratio ofabout
3.5, with a very wide standard deviation.
If a few of the highest gonad dose ratios
are omitted (four entries with ratios> 10),
the mean and standard deviations are 2.6
and 1.67, respectively. Thus, it appears
that the gonad dose ratio is typically a fac-
tor of 2 to 3, but that it can vary widely.
Advisory
Cessation
12hr
24hr
Cessation
Comments
12hr
12hr
12hr
No consideration offree iodide
24 hr No consideration offree iodide
No consideration offree iodide
No consideration offree iodide
168hr
Fraction of administered activity
(0.41)treated as iv DTPA
24 hr Treated asTc-99m pertechnetate
Treated as Tc-99m DTPA
Therefore, a woman carries a somewhat
higher radiation burden than her male
counterpart, given the same amount of
activity administered per study. If the
activity given were scaled based on indi-
vidual body mass, however, at least the
critical organ and effective dose differences
would be eliminated. This is not routine
in nuclear medicine practice. The amount
of activity administered is often scaled by
body mass in pediatric studies, but in
adults, generally the same amount ofactiv-
ity is given, based on a number ofcriteria,
so the differences reported here are gener-
ally realized in practice. Breast doses
(Table 3, Figure 4) vary widely between
procedures, from a few Gy per MBq, to a
few tens ofmGy per MBq.
Fetal doses for most radiopharmaceuticals,
when expressed on the basis ofdose to the
fetus per unit activity administered to the
mother, for most radiopharmaceuticals
tend to decrease throughout gestation. As
the baby grows, the absorbed fractions for
the fetus absorbing radiation from mater-
nal organs will increase, but the baby's
increase in mass generally offsets this
increase (recall that absorbed dose is energy
absorbed per unit mass). Exceptions to this
occur in cases in which there is a consider-
able increase in the placental crossover of
the radiopharmaceutical as pregnancy pro-
gresses, which increases fetal self-dose.
Some exceptions also occur for certain
organs in the mother's body for which the
specific absorbed fraction increases
throughout gestation, notably the liver,
lungs, and spleen (6). The doses shown in
this report give only the average absorbed
dose to the whole fetus; current models
do not permit adequate modeling of the
dose to individual organs within the fetus,
although this may be quite important in
many circumstances. Some authors
(11,12) have attempted on an individual
basis to make such individual organ dose
estimates. The most notable of these
inquiries is that of Watson (11), who
demonstrated clearly the importance ofthe
dose to the fetal thyroid for iodine (espe-
cially I-131) administration to women after
week 10 ofgestation.
The dose estimate analysis for the
nursing infant reveals that for many radio-
pharmaceuticals no interruption of breast
feeding is indicated, even given the rela-
tively low effective dose equivalent criterion
of 1 mSv EDE and a use ofthe worst case
values of breast milk concentration and
elimination half-time. Many radiopharma-
ceuticals have short physical half-lives and
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decay quickly after administration. Also,
because of their short half-lives and their
radiation spectrum, most of these nuclides
give a fairly low dose per unit intake. A few
ofthe Tc-99m compounds and one I -123
compound required short interruption
periods so as not to exceed the 1-mSv
effective dose equivalent value. A differ-
ence was seen between in vivo- and in
vitro-labeled Tc-99m red blood cells, as
the former have a higher assumed fraction
of free pertechnetate in the injectate-
Tc-99m pertechnetate required a 24-hr
interruption to satisfy the dose criterion.
The most important compounds in the
analysis were 1-131 NaL, Ga-67 citrate, and
Tl-201 chloride. Because of either their
long physical or biological half-times or
their high radiation dose per unit intake
values, or both, these compounds have the
potential for relatively high infant doses,
and if these studies are used, cessation of
breast feeding is probably indicated.
In summary, it is clear that there are
special concerns with regard to the female
nuclear medicine patient in the risk/benefit
analyses. The most important concerns arise
when a woman is either pregnant or breast
feeding, but the slightly higher organ and
gonad radiation burdens a woman carries
compared to her male counterpart are also
ofinterest. A logical extension ofthis work
would be to apply the amount of activity
administered per study and the number of
nuclear medicine studies performed on men
and women for each type of study and to
examine the population doses identified in
routine nuclear medicine practice. Such
information was not available at the time of
this writing, but this study provides infor-
mation that could be used for this analysis
should it be undertaken.
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